Akèy › Limfom Selil-T › New York › New York City
Etid klinik pou Limfom Selil-T nan New York City, NY
13 etid pou Limfom Selil-T ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Columbia University, New York
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Ap rekriteFaz 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Ap rekriteFaz 3
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
CD4CAR for CD4+ Leukemia and Lymphoma
Ap rekriteFaz 1
- Albert Einstein Health Network, New York
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Ap rekriteFaz 1/2
- Memorial Sloan Kettering, New York
A Registry for People With T-cell Lymphoma
Ap rekriteEtid obsèvasyon
- Weill Cornell Medical Center (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Ap rekriteFaz 2
- Icahn School of Medicine at Mount Sinai, New York
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
Ap rekriteFaz 1
- Columbia University Irving Medical Center, New York
Tissue Repository: CTCL Collection Protocol
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Columbia University Irving Medical Center, New York
MB-105 in Patients With CD5 Positive T-cell Lymphoma
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Ap rekriteFaz 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Etid Limfom Selil-T nan lòt vil
- Philadelphia, PA10 etid
- Baldwin Park, CA9 etid
- Boston, MA9 etid
- Houston, TX8 etid
- Atlanta, GA8 etid
- Rochester, MN6 etid
- Columbus, OH6 etid
- Chicago, IL6 etid
- Seattle, WA6 etid
- Miami, FL5 etid
- New Haven, CT5 etid
- Scottsdale, AZ4 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.